Home / Recalls / Sciegen Pharmaceuticals Inc / D-0354-2023

D-0354-2023 Class III Terminated

Recalled by Sciegen Pharmaceuticals Inc — Hauppauge, NY

Recall Details

Product Type
Drugs
Report Date
March 8, 2023
Initiation Date
February 17, 2023
Termination Date
June 17, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4,392 bottles

Product Description

Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05.

Reason for Recall

Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

Distribution Pattern

Nationwide in the USA and Puerto Rico

Code Information

Lot # G177092, Exp. 11/24

Other recalls by Sciegen Pharmaceuticals Inc

  • D-0271-2019 Class II — GSMS Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 60429-641-30), (b (October 29, 2018)
  • D-0268-2019 Class II — Westminister Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 69367-120 (October 29, 2018)
  • D-0267-2019 Class II — Westminister Irbesartan Tablets, USP, 75 mg (a) 30-count bottle (NDC 69367-119-0 (October 29, 2018)
  • D-0270-2019 Class II — GSMS Irbesartan Tablets, USP, 75 mg, 30-count bottle, Rx Only, Manufactured by S (October 29, 2018)
  • D-0272-2019 Class II — GSMS Irbesartan Tablets, USP, 300 mg,(a) 30-count bottle (NDC 60429-642-30), (b) (October 29, 2018)
  • D-0269-2019 Class II — Westminister Irbesartan Tablets, USP, 300mg, Rx Only,(a) 30-count bottle (NDC 69 (October 29, 2018)